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Left ventricular assist device (LVAD)
Background: Intracranial hemorrhages associated with new generation left ventricular assist devices
(LVAD) are increasingly reported as the use of these life saving devices is becoming more common, but
few data are currently available to guide the acute management of these critically ill patients.
Methods: This is a case presentation of a 33-year-old woman status post LVAD implantation on
therapeutic anticoagulation who developed acute headache followed by rapidly progressive impairment
of consciousness secondary to spontaneous subarachnoid hemorrhage and hydrocephalus.
Results: After discontinuation of heparin infusion, the patient underwent external ventricular drain
placement(EVD)and her mental status fully recovered. Her work-up was negative for aneurysmal
sources of bleeding. She received daily aspirin for 7 days for antiplatelet effect during which she did not
experience any thromboembolic events related to the LVAD. At day 6 the EVD was clamped for 24 hours
and her neurological exam remained intact. The EVD was removed and she was restarted on heparin
infusion without further complications.
Conclusions: Our experience suggests that in case of subarachnoid hemorrhage in patients with
LVADs, temporary suspension of anticoagulation and EVD placement is safe and can lead to good
neurological outcome.
© 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Intracranial hemorrhages associated with new generation left
ventricular assist devices (LVAD) are increasing as the use of these
life saving devices is becoming more common [1]. Recent series
showed that 3–11% of LVAD patients suffered an intracranial bleed
[2,3]. However, there remains little data to guide the management
of these critically ill patients. Herein we report the case of an LVAD
patient who developed acute hydrocephalus after a spontaneous
subarachnoid hemorrhage (SAH) while anticoagulated, who was
successfully managed with suspension of anticoagulation and
cerebrospinal ﬂuid diversion through an external ventricular
drain (EVD)., University of Cincinnati,
.: +1 513 5692618; fax: +1
c. Open access under CC BY-NC-NDCase report
A 33 year old woman with a history of congenital heart disease,
coarctation of the aorta, and ventricular septal defect status-post
Ross procedure as a child, with systolic heart failure and chronic
kidney disease (glomerular ﬁltration rate=40), underwent Heart-
mate II LVAD implantation as destination therapy 3 months prior to
presentation. Per standard of care she was anticoagulated with
warfarin to a target INR of 2.5–3.5 and took full dose aspirin for
antiplatelet effect. She underwent tracheostomy post LVAD
implantation for chronic respiratory failure but had no baseline
neurologic dysfunction. She initially presented to an outside
institution because of acute decompensated heart failure and
concurrent pneumonia with preserved LVAD function. Her warfarin
was discontinued and she was placed on unfractionated heparin
infusion. Anti-Xa levels and PTT levels remained within therapeutic
range. Her warfarin was sub-therapeutic on admission (INR=1.3)
but the reasons for heparin infusion and warfarin discontinuation
were not reported. Three days after admission she developed
severe headache and nausea followed by encephalopathy and
increased somnolence. Her head CT demonstrated diffuse license.
Fig. 1. Head CT obtained 14 hours after diagnosis of SAH because of increased lethargy. Imaging demonstrates hydrocephalus and subarachnoid hemorrhage within the
interpeduncular cisterns extending into the fourth ventricle, cerebral aqueduct and third ventricle.
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extending into the upper cervical spinal cord with associated
hydrocephalus, WFNS GRADE 2. Heparin infusion was stopped but
protamine was not administered. A limited two-vessel digital
subtraction angiogram (DSA) was performed and did not identify a
source of bleeding. A few hours after the DSA, she became more
lethargic and was transferred to our Neuroscience Intensive Care
Unit (NSICU). Upon arrival she was comatose, only withdrawing
both lower extremities to noxious stimulation. Her Glasgow Coma
Scale was 6 T (E = 1, T, M = 4). Her arrival CT showed stable SAH
within the interpeduncular cisterns and additional subarachnoid
blood along the inferior aspect of the right temporal lobe and
inferior cerebellum with interval worsening of hydrocephalus
(Fig. 1). Her arrival INR was 1.5, PT was 17.5 and PTT was 35.7.
An emergent EVD was placed with a right frontal approach and
cerebrospinal ﬂuid diversion was started at 15 mmHg. Soon after
the procedure her mental status improved, she began to follow
commands and mouth words (Glasgow Coma Scale = 11 T). The
initial DSA was reviewed and considered non diagnostic as did not
include the anterior circulation. Risks and beneﬁts of a second dye
load in a patient with chronic kidney failure in light of a possible
unsecured ruptured aneurysm were weighted and we decided to
perform a second DSA which ruled out the presence of aneurysms
or vessels anomaly. Her renal failure remained stable and she was
continued on aspirin 81 mg daily for LVAD care to prevent
thromboembolic events. She required dobutamine, milrinone and
furosemide continuous infusions to support her decompensated
heart failure and her respiratory insufﬁciency. The heart failure
consult team followed her care and ancillary nursing staff from the
cardiovascular ICU provided support to the NSICU nursing staff for
the daily care of the LVAD. During her NSICU course, there were no
thromboembolic complications or LVAD events. Her EVD was
clamped for 24 hours 6 days later and her neurologic exam
remained stable. A head CT performed 24 hours after clamping
showed stable ventricular size. The EVD was then removed and
anticoagulation with heparin infusion was restarted seven days
after ictus. Her mental status returned to baseline and she had no
neurologic sequelae of her SAH. Despite her neurologic recovery,
she continued to have refractory systolic heart failure complicated
by worsening pulmonary hypertension and she was transferred
back to the institution that had implanted her LVAD for further
management of her cardiac disease.Discussion
LVADs provide survival beneﬁt and improve quality of life in
patients with advanced heart failure and have been increasingly
used either as a bridge to transplantation or as destination therapy
[1]. Newer generation mechanical devices use a continuous-ﬂow
pump and require long-term anticoagulation therapy with both
warfarin and antiplatelet drugs to prevent thromboembolic events.
Common complications of LVAD implantation are primarily related
to bleeding, most notably in the gastro-intestinal tract and the
central nervous system. Bleeding complication rates range from
17.5% to 63/100 patient years [4]. Whether these bleeding events
are solely a consequence of anticoagulation therapy has been
questioned. LVADs expose blood to shear stress thatmay contribute
to breakdown of von Willebrand factor (vWF) multimers,
compromising platelet aggregation [5]. Several studies have
shown that LVADs can alter hemostatic factors and cause acquired
von Willebrand syndrome [6] analogous to the bleeding diathesis
observed in aortic stenosis [7]. Studies reported rates of ICH in
LVAD patients on anticoagulation that vary from 3 to 11 % [2,3,8].
The REMATCH trial (Randomized Evaluation of Mechanical Assis-
tance for the Treatment of Congestive Heart Failure) reported 2
fatal hemorrhages among 68 LVAD patients [9]. Our patient likely
suffered from a spontaneous perimesencephalic non aneurysmal
SAH (PNSH) as suggested by negative DSA. PNSH are associated
with a favorable outcome but can be complicated by symptomatic
hydrocephalus that requires emergent CSF diversion [10].
Few data are available to guide the management of intracranial
bleeding complications in LVAD patients in terms of associated risk
of withholding anticoagulation, length of suspension and surgical
intervention. Since our patient required CSF diversion to treat SAH-
related obstructive hydrocephalus, we decided to withhold intra-
venous heparin while the EVD remained in place and continue
aspirin to balance the risk of intracranial bleeding and thrombo-
embolic events. Different anticoagulation strategies after hemor-
rhagic complications in LVAD patients have been described in the
literature [11–13]. In the study conducted by Wilson at al. on 36
LVAD patients who suffered an intracranial bleed, aspirin was
withheld in 47% of patients and warfarin therapy was withheld in
61%. The median duration of suspension was 6 days for aspirin and
10.5 days for warfarin. No clinically signiﬁcant thromboembolic
events or pump failures were observed [2]. Other studies suggested
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hemorrhagic complications [14,15].
Conclusion
Our experience shows that EVD placement for CSF diversion in
case of SAH induced hydrocephalus with temporary interruption of
anticoagulation and continuation of aspirin is a lifesaving proce-
dure that can lead to good neurological outcome and ought to be
considered in the appropriated setting. Importantly, these patients
commonly present with complex comorbidities related to their end
stage heart failure and collaborative care is essential to their
outcome. While intracranial bleeding has been thought to be a
universally fatal event for patients with implanted LVADs, we
believe that this is not, in fact, the case and that aggressive
management of these patients in neurocritical care intensive care
units may lead to good outcomes and neurologic recovery.
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